MARKET

QLGN

QLGN

Qualigen Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.420
-0.020
-1.39%
After Hours: 1.450 +0.03 +2.11% 18:04 09/24 EDT
OPEN
1.420
PREV CLOSE
1.440
HIGH
1.440
LOW
1.400
VOLUME
163.74K
TURNOVER
--
52 WEEK HIGH
5.47
52 WEEK LOW
1.160
MARKET CAP
41.18M
P/E (TTM)
-3.1031
1D
5D
1M
3M
1Y
5Y
Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
CARLSBAD, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO a...
GlobeNewswire · 09/15 11:30
Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present at the H.C. ...
GlobeNewswire · 09/08 11:30
QLGN: Focusing on Advancement of QN-247 and RAS-F…
By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT
Benzinga · 09/05 11:00
ACST, AMSC and NETE among mid-day movers
Gainers: Regional Health Properties (NYSE:RHE) +55%. AC Immune (NASDAQ:ACIU) +34%. Net Element (NASDAQ:NETE) +27%. Vallon Pharmaceuticals (NASDAQ:VLON) +25%. Spok (NASDAQ:SPOK) +23%. Elys Game Technology (NASDAQ:ELYS) +21%. Youdao (NYSE:DAO) +20%. Qualigen
Seekingalpha · 08/31 16:54
Qualigen Therapeutics Shares See Volume; Zacks Small-Cap Research Sets $9 Valuation
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_08312021_QLGN_Bautz.pdf
Benzinga · 08/31 15:47
Regional Health Properties, AC Immune leads healthcare gainers; RenovoRx, Poseida Therapeutics among major losers
Gainers: Regional Health Properties (NYSE:RHE) +53%, AC Immune (NASDAQ:ACIU) +39%, Regencell Bioscience (NASDAQ:RGC) +29%, Qualigen Therapeutics (NASDAQ:QLGN) +19%, Reneo Pharmaceuticals (NASDAQ:RPHM) +17%. Losers: RenovoRx (NASDAQ:RNXT) -21%, Poseida Ther...
Seekingalpha · 08/31 15:11
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 08/23 13:58
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of QLGN. Analyze the recent business situations of Qualigen Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average QLGN stock price target is 7.75 with a high estimate of 9.00 and a low estimate of 6.50.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 2.83M
% Owned: 9.76%
Shares Outstanding: 29.00M
TypeInstitutionsShares
Increased
8
805.52K
New
3
218.24K
Decreased
4
244.64K
Sold Out
6
137.97K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Poirier
Chief Financial Officer/Vice President - Finance
Christopher Lotz
Chief Operating Officer/Vice President
Shishir Sinha
Executive Vice President/Director
Amy Broidrick
Senior Vice President
Tariq Arshad
Chief Scientific Officer/Vice President - Research & Development
Wajdi Abdul-Ahad
Director
Ira Ritter
Independent Director
Richard David
Independent Director
Sidney Emery
Independent Director
Matthew Korenberg
Independent Director
Kurt Kruger
No Data
About QLGN
Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotechnology company. The Company is focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as development of its FastPack diagnostic platform. Its pipeline includes AS1411, Aptamer Linked Anti Nucleolin (ALAN), Aptamer Linked Anti Nucleolin - Contrast Enhancement (ALAN-CE), Aptamer Linked Anti Nucleolin - Radiation Enhancement (ALAN-RE), Selective Target Antigen Removal System (STARS) and RAS-F. The FastPack System is an immunoassay testing system, which consists of the FastPack Analyzer and the FastPack test pouch, a single-use, disposable, foil packet which includes the FastPack reagent chemistry. The Company’s subsidiary is Qualigen, Inc.

Webull offers kinds of Qualigen Therapeutics Inc stock information, including NASDAQ:QLGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QLGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QLGN stock methods without spending real money on the virtual paper trading platform.